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Abstract
Background: Pseudomonas aeruginosa is the predominant pathogen associated with the decline of pulmonary
function in cystic fibrosis (CF) patients. Both environment-to-host acquisition and patient-to-patient transmission
have been described for P. aeruginosa infection. Epidemic clones and bacterial phenotypic adaptation to the CF
lung have been recognised as independent risk factors for disease progression. So far, there is no established link
between genotypic prevalence and phenotypic traits. Here, we look at the major CF patient cohort in Italy to
identify shared P. aeruginosa clones and associated common phenotypic traits.
Results: A comprehensive analysis of P. aeruginosa genotypes to determine the presence of high-risk shared clones
and their association to specific phenotypic traits has been performed in a major Italian CF centre. Pulsed-field gel
electrophoresis (PFGE) of P. aeruginosa isolates from 338 CF subjects identified 43 profiles shared by two or more
patients and 214 profiles exclusive to individual patients. There was no evidence of a P. aeruginosa outbreak, but
four most prevalent pulsotypes were detected. Common phenotypic traits were recorded intra-pulsotypes, but we
detected heterogeneity inter-pulsotypes. Two of the four major pulsotypes included P. aeruginosa isolates with
hallmarks of adaptation to the CF airways, including loss of motility, low production of siderophore, pyocyanin and
proteases, and antibiotic resistance. One of these pulsotypes grouped a high percentage of hypermutable isolates.
No clear correlation between epidemiological and clinical data was found.
Conclusions: We conclude that CF patients of this cohort shared common pulsotypes, but their phenotypic
heterogeneity indicates an absence of specific traits associated to P. aeruginosa genotypic prevalence.
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Background
Pseudomonas aeruginosa is the most common respiratory
pathogen in patients with cystic fibrosis (CF) infecting ap-
proximately 80 % of subjects, starting from adolescence
[1]. The predominant mechanism by which P. aeruginosa
is acquired is controversial. Few dominant clones,
including P. aeruginosa PA14 and clone C strain, are dis-
tributed worldwide and highly prone to infect CF patients,
suggesting environment-to-host acquisition [2, 3]. How-
ever patient-to-patient transmission of P. aeruginosa has
been increasingly reported in a few CF centres [4]. So far,
few strains, such as clone C and the Liverpool epidemic
strain (LES), have been indicated as highly pathogenic and
transmissible causing epidemics within and between sev-
eral CF clinics [5–9]. LES and the Melbourne strains have
also been associated with a worse prognosis and higher
rates of mortality, respectively [10, 11]. Thus, person-to-
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person P. aeruginosa transmission may represent a serious
threat for CF patients, and this has opened a debate on in-
fection control issues and the management of CF patients.
The pathogenicity of P. aeruginosa in CF is promoted
by the diversification of the bacterial population and the
presence of multiple phenotypes [12]. Common pheno-
typic traits, such as mucoidy, immotility, type-III secretion
system deficiency, lasR mutation, hypermutability and
lipopolysaccharide (LPS) modifications are consistently
acquired by most P. aeruginosa strains to promote long-
term persistence in CF patients. Few of these P. aerugi-
nosa phenotypes (e.g. mucoidy, lasR mutant phenotype
and hypermutability) have been associated with the more
severe lung function [13–15]. While it is well-established
that the bacterial intensive genetic adaptation has a key
role in the progression of chronic lung infection, the link
between specific P. aeruginosa phenotypic traits and geno-
typic prevalence remains to be established.
In this study we addressed a comprehensive analysis of
P. aeruginosa genotypes at the CF centre in Verona,
Italy, to establish the presence of a prevalent clone due
to possible patient-to-patient transmission and its asso-
ciation to specific phenotypic traits. Results did not
point to the presence of a P. aeruginosa outbreak,
though sporadic events of possible transmission may
have occurred. However, we detected prevalent pulso-
types which are characterised by phenotypic heterogen-
eity. These data indicate the absence of specific traits in
P. aeruginosa isolates among prevalent pulsotypes.
Methods
Patients and bacterial strains
Between July 2008 and April 2009, 1,352 clinical isolates
of P. aeruginosa were sampled from 338 patients with
CF attending the CF centre in Verona. Patients were
followed prospectively and only those intermittently or
chronically colonised were selected for the study. Isola-
tion and identification of P. aeruginosa from sputum
were carried out by plating onto MacConkey agar and
incubating for 48–72 h, and by API system 20NE (bio-
Merieux SA, Lyon, France). Provisional isolate differenti-
ation was made on the basis of colony size, morphology,
pigmentation (visual assessment), and mucoidy. P. aeru-
ginosa isolates were stored at −80 °C in the MAST
CRYOBANK™ (Mast Diagnostics, Bootle, United
Kingdom). In the CF centre, patients undergo routine
sputum culture four times a year. One positive culture
for each CF patient was selected for this study. Four P.
aeruginosa isolates were collected from this positive cul-
ture, and one was blindly chosen for detailed analysis.
Isolates genotyping
Pulsed Field Gel Electrophoresis (PFGE) of P. aeruginosa
isolates was performed using the Genepath System
apparatus and the CHEF Bacterial Genomic DNA Plug
kit (Bio-Rad Laboratories, Hercules, USA), following the
protocol by Grundmann et al. [16]. DNA band patterns
were analysed with InfoQuest FP software version 5.1
(Bio-Rad Laboratories, Hercules, USA), using the Dice
correlation coefficient and Unweighted Pair Group
Method with Arithmetic Mean (position tolerance and
optimisation of 1.5 %) [17]. By applying the criteria of
Tenover and colleagues [17], based on the differences in
the numbers of bands, we identified a cut-off value of
90 % similarity to correctly cluster the PFGE profiles. A
cluster was consequently defined as a group of isolates
showing ≥90 % similarity of the PFGE profile.
Isolates phenotyping
Swimming and twitching capacities were evaluated as
described [18]. Proteases, siderophore and pyocyanin se-
cretion, mutation frequency and lasR mutant phenotype
were assayed as described in the Additional file 1.
Minimum Inhibitory Concentrations (MIC) measurement
MICs were determined according to Clinical and
Laboratory Standards Institute (CLSI) guidelines [19].
MIC90 is the concentration active against 90 % of
microorganisms tested. Isolates were defined as
multidrug-resistant (MDR) and extensively drug-
resistant (XDR) according to the terminology approved
by the European Centre for Disease Prevention and
Control (ECDC) and the Centres for Disease Control
and Prevention (CDC) [20].
Results
Patients with CF
The clinical data of CF patients selected for the study,
including FEV1 (Forced Expiratory Volume in 1 s) and
their F508del mutation status, are shown in Additional
file 1: Table S1. Of the 338 patients, 161 were males
and 177 females. The mean age at enrollment was
26.7 years (range 1–50 years). Nineteen pairs of sib-
lings, including four pairs of twins, were included in
the study. Seventy-eight patients were homozygous and
147 heterozygous for F508del. The mean FEV1 at the
time of patient enrollment was 61.5 (range 17–126).
The percentage of patients chronically colonised (at
least three positive cultures recorded with at least one
month intervals between them) by P. aeruginosa was
50 %, while the rest were intermittently colonised (with
only one or two positive cultures), according to the
European Consensus [21].
Genomic profile of P. aeruginosa isolates
PFGE was carried out for all 338 P. aeruginosa isolates.
By setting the similarity cut-off at 90 %, 214 PFGE pro-
files were classified as unique pulsotypes of single
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patients (Fig. 1). Of the 43 clusters of strains detected,
25 clusters included at least two or more P. aeruginosa
isolates showing identical PFGE profile (100 % similarity)
or belonging to highly related subtypes (≥90 % similar-
ity), and these were classified as “PFGE patterns” (P).
The remaining 18 clusters grouped two or more P. aeru-
ginosa isolates which were highly related to each other
(≥90 % similarity), but none of them identical, and these
were classified as “PFGE correlated profiles” (CP). Four
major PFGE clusters, including more than three isolates,
were detected: P1, P6, P14 and CP2 (Fig. 2). The con-
tacts investigation showed no clear link among patients
with the same PFGE profile. Cluster P1 included P. aeru-
ginosa isolates from eight CF patients, distributed in four
highly related subtypes. Two P1 subtypes (P1.0 and
P1.1) included three indistinguishable P. aeruginosa iso-
lates each. Cluster P6 included isolates from six patients,
five of them identical (100 % similarity) (P6.0) and one
highly related (97 % similarity) to subtype P6.0. Cluster
P14 included isolates from 12 patients, distributed in six
highly related subtypes, one of them grouping four in-
distinguishable isolates (P14.0) and three grouping two
indistinguishable isolates each (P14.1, P14.2 and P14.3).
Cluster CP2 included isolates highly related to each
other derived from eight CF patients’ clustering with a
similarity ≥90 % (CP2.0 – CP2.7). The remaining 304
isolates presented unique PFGE profiles (63.3 % of the
total strains) or were included in other minor PFGE
clusters, grouping two or three P. aeruginosa isolates
(26.6 %) with a similarity of at least 90 %. One pair of
siblings harboured an indistinguishable genotype (P13),
while two pairs were infected by highly related P. aerugi-
nosa isolates (CP7 and CP18). The genotype and the
characteristics of patients with P. aeruginosa isolates be-
longing to the prevalent PFGE clusters (P1, P6, P14 and
CP2) are reported in Table 1 and summarized in Table 2.
Overall, these findings indicate that a P. aeruginosa out-
break was not found, despite the presence of prevalent
pulsotypes, potentially due to sporadic cross-transmission.
Phenotypic characterisation of the major P. aeruginosa
clusters
Phenotypic characterisation was carried out on 34 P. aeru-
ginosa isolates belonging to the four prevalent clusters
(P1, P6, CP2, P14) identified by PFGE analysis (Fig. 2,
Additional file 1: Table S2). Most of the isolates in cluster
P1 were non-mucoid (75 %), motile (62.5 % with twitching
and 75 % with swimming motility), protease, siderophore
and pyocyanin producers (respectively 62.5, 87.5 and
62.5 %), non-hypermutable (100 %), lasR wt (87.5 %); two
isolates were XDR and one isolate was MDR (at least
MDR: 37.5 %) [20]. Isolates belonging to cluster P6 were
prevalently non-mucoid (66.7 %), non-motile (100 % lack-
ing both twitching and swimming motility), protease and
siderophore low-producers (100 % lacking both protease
and siderophore secretion), lasR wt (100 %), hypermutable
(83.3 %) and pyocyanin low producers (100 %). Three iso-
lates were XDR and one was MDR (at least MDR: 66.7 %).
Isolates of cluster P14 were mainly non-mucoid (66.7 %),
non-motile (100 % lacking both twitching and swimming
motility), protease and siderophore low-producers (100 %
lacking protease and 83.3 % lacking siderophore secre-
tion), lasR mutated (91.7 %), non-hypermutable (91.7 %)
and pyocyanin low-producers. Five isolates were XDR and
three were MDR (at least MDR: 66.7 %). Cluster CP2 in-
cluded isolates mainly non-mucoid (75 %), non-motile
(62.5 % lacking both twitching and swimming motility),
protease non-secreting (100 %), siderophore secreting
(100 %), non-hypermutable (100 %), lasR mutated
(62.5 %); none of the isolates was MDR or XDR. Notably,
no clear difference in antimicrobial resistance between
isolates from intermittently and chronically colonised/in-
fected patients within the same PFGE profile was ob-
served. Overall, these results demonstrate the phenotypic
heterogeneity among major pulsotypes.
Considering all the isolates of the four clusters, it
should be pointed out that only a few were mucoid even
though several patients were chronically infected. De-
crease in the twitching and swimming motility, reduced
protease, siderophore and pyocyanin secretion, lasR mu-
tant phenotype, hypermutability and MDR phenotype,
which are hallmarks of bacterial adaptation, were de-
tected prevalently in cluster P6 (Fig. 3).
Discussion
This work provides the results of the genotypic charac-
terisation of P. aeruginosa isolates collected from 338
Fig. 1 Distribution of isolates among profiles of different sizes. P.
aeruginosa isolates were subjected to PFGE and DNA band patterns
were analysed. The distribution of isolates among the profiles is shown
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patients at the CF centre in Verona between 2008 and
2009. The objective was to establish the presence of a
high-risk outbreak due to possible patient-to-patient
transmission. The PFGE analysis revealed the presence
of 43 clusters that included isolates from two to 12 pa-
tients, indicating possible transmission in this clinic.
However, a P. aeruginosa outbreak was not evident.
In this study the prevalent cluster included 12 subjects
representing the 3.6 % of all the CF patients recruited.
In other surveys which identified PFGE profiles shared
by 7–20 % of patients, the authors concluded that the
risk of cross-colonisation was extremely low [22–24].
According to these criteria, at the CF centre in Verona
the risk of patient-to-patient transmission is low, al-
though it cannot be excluded in some cases. It has been
reported that different management of the P. aeruginosa
infections in terms of antimicrobial chemotherapy and
infection control is probably responsible for the discord-
ant epidemiology [25]. At the CF centre in Verona,
strong antibiotic treatment was administered only in the
presence of pulmonary exacerbations and for eradication
protocols. Overall, the pre-existing rules for infection
control in this CF centre and the strategy of eradicating
P. aeruginosa when isolated for the first time may have
counteracted outbreaks of epidemic strains, as shown by
our results. Moreover, the structure and organisation of
this centre changed in 2012, in accordance with the in-
fection control policies suggested in the European Con-
sensus for the standards of care for CF patients [26].
The implementation of infection control strategies may
have further reduced the risk of cross-transmission com-
pared to the study period analysed (2008–2009).
The long-term colonisation of CF patients’ airways by
P. aeruginosa selects clonal patho-adaptive variants with
Fig. 2 Genotypic and phenotypic characterisation of P. aeruginosa isolates belonging to the four more frequent PFGE profiles. PFGE dendrograms
of the four major clusters (P1, P6, P14, CP2) are reported. Phenotypic traits of adaptation to CF airways and intermittent or chronic status of
isolates are indicated. Resistance to at least one member of a specific antibiotic class is indicated as +. * swimming and twitching motility zone
diameter, as measured by subsurface stab assay; ° halo diameter; # isolates with iridescent and metallic sheen of the colony surface, that is typical
for a lasR mutant, are indicated as +; § visible pyocyanin presence +; no visible pyocyanin -; Abbreviations: Isol isolate, Patt PFGE pattern, I/C intermittent or
chronic, Muc mucoidy, Twitch twitching motility, Swimm swimming motility, Prot proteases, Sider siderophores, Hyper-mut hyper-mutability (mutation
frequency), Pyoc pyocyanin, aminogl aminoglycosides, mono-bact mono-bactams, cephal cephalosporins, fluoroq fluoroquinolones, carbap carbapenems,
pen/β-lact inh penicillins/β-lactamase inhibitors, sulfon/folate ant sulfonamides/folate antagonists
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different features compared to the initially acquired
strain [27]. Of these features, the most frequently de-
scribed are the loss of invasive functions such as twitch-
ing and swimming motility or virulence factors as
pyocyanin, several proteases, acquisition of mucoid and
hypermutable phenotype. These phenotypic changes
favour the persistence of P. aeruginosa variants in the
CF lung. Despite the well-known relevance of P. aerugi-
nosa phenotypes, associated to adaptation to the CF
airways, to the progression of lung disease, as far as we
are aware this is the first work which attempts to exam-
ine the link between predominant P. aeruginosa pulso-
types and phenotypic traits. Our phenotypic analysis
showed that, despite a phenotypic homogeneity within
the pulsotype, the clusters were heterogeneous when
compared with each other, indicating an absence of spe-
cific traits characterising the predominant pulsotypes.
More importantly, these data indicate that the potential
Table 1 Demographics of CF patients harbouring P. aeruginosa isolates belonging to the most representative patterns
Isolate Pattern Subtype Sex Age (yrs range) FEV1 (% predicted) P. aeruginosa status Age at 1
st P. aeruginosa
isolation (range)
113 P1 P1.1 F 46–50 31 C 26–30
121a P1 P1.1 M 6–10 54 C 0–5
96b P1 P1.1 F 21–25 82 I 16–20
20A P1 P1.2 F 26–30 68 I 0–5
109b P1 P1.3 M 36–40 52 C 31–35
105 P1 P1.0 M 31–35 66 C 0–5
106 P1 P1.0 M 36–40 70 C 21–25
107b P1 P1.0 M 41–45 84 I 26–30
49b P6 P6.0 M 34 39 C 6–10
14 P6 P6.0 M 36–40 41 C 16–20
163b P6 P6.0 F 16–20 112 I 6–10
286 P6 P6.0 F 21–25 27 C 0–5
45 P6 P6.0 F 26–30 43 I 16–20
100a P6 P6.1 F 31–35 48 I 11–15
239a P14 P14.2 M 21–25 55 I 0–5
27b P14 P14.2 M 21–25 96 I 11–15
23b P14 P14.0 M 26–30 55 C 0–5
262 P14 P14.0 F 31–35 82 C 16–20
62b P14 P14.0 M 31–35 55 C 16–20
94b P14 P14.0 F 31–35 50 I 16–20
31 P14 P14.4 F 31–35 26 C 16–20
272a P14 P14.1 M 11–15 105 C 6–10
90 P14 P14.1 F 21–25 64 C 0–5
58 P14 P14.5 F 16–20 39 C 11–15
192b P14 P14.3 M 26–30 100 I 0–5
228b P14 P14.3 M 31–35 29 I 11–15
162 CP2 CP2.5 M 21–25 61 C 0–5
12A CP2 CP2.4 F 11–15 51,8 C 0–5
115b CP2 CP2.7 M 36–40 79 C 21–25
83b CP2 CP2.1 M 11–15 100 C 0–5
186b CP2 CP2.0 F 6–10 115 I 6–10
154 CP2 CP2.3 F 31–35 76 I 6–10
187 CP2 CP2.2 F 41–45 50 I 21–25
292 CP2 CP2.6 M 36–40 51 I 21–25
Abbreviations and symbols: M male, F female, FEV1 forced expiratory volume in 1 s, C chronic, I intermittent;
a F508del +/+; b F508del +/−
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patient-to-patient transmission cannot be due to a spe-
cific P. aeruginosa phenotypic trait analysed in this
study. However, we cannot exclude that other adaptive
traits (e.g., metabolic changes, lipopolysaccharide modifi-
cations) may be involved in cross-transmission.
Among the limitations of this study, we acknowledge
that environmental microbiologic sampling was not
performed. As a consequence we cannot exclude that
the most common pulsotypes were acquired from an
environmental source. In addition, we only tested a sin-
gle P. aeruginosa isolate per sputum sample. A previous
study reported that the great majority of patients only
harbour a unique genotype [28]. However, co-infection
with multiple P. aeruginosa isolates is also well-
described in CF patients [29, 30]. Secondly, this study
relied on the analysis of isolates recovered from the
sputum. And although sputum culture appears to be a
reliable means for detecting P. aeruginosa in the lower
airways [31], it should be considered that different re-
gions of the CF lung may be colonised by different iso-
lates. We cannot exclude that other strains may be
dominant in other regions of the CF lung, e.g. the more
distal areas which are difficult to access, and probably
affected by more stringent environmental conditions
(e.g. oxygen depletion). Overall, these two limitations
may lead to an underestimation of the prevalent pulso-
types, and of the genetic variability among P. aerugi-
nosa isolates. The choice to use PFGE as a typing tool
may also be questionable, as it is expensive, labour-
intensive and does not allow comparisons with data
from other groups, different to the multilocus sequence
typing (MSLT) and random amplified polymorphic
DNA (RAPD). However, PFGE was considered to be
the gold-standard method for microbial typing when
the survey was initiated. Recently it was shown that the
discriminatory power of PFGE, MSLT and RAPD are
comparable [32]. Furthermore, while MSLT was shown
to be highly predictive in labelling strains as unique,
PFGE was the best technique for predicting clonality.
Despite all the criticisms, there is no evidence to sup-
port the claim of an outbreak at the CF centre in Ver-
ona, although the risk of cross-transmission among
patients cannot be excluded.
Conclusions
This survey suggested an absence of a P. aeruginosa out-
break at the CF centre in Verona, despite the presence
of prevalent clusters which may suggest cross-
transmission in a few of the cases. We suggest that strict
segregation procedures for infection control and the
strategy of first eradication of P. aeruginosa may have re-
duced the incidence of nosocomial transmission. These
surveillance studies, although complex and expensive,
have the potential to monitor the emergence of epidemic
high-risk clones and implement infection control strat-
egies within the CF centres. In addition, the inter-
pulsotypes phenotypic heterogeneity described in this
work indicated the absence of specific traits associated
to major pulsotypes. Further studies are needed to rule
out any contribution of other determinants to
transmission.
Table 2 CF patient demographics
Pattern (N°
of patients)




Mean age at the first
colonisation (yrs)
Annual median rate of decline in FEV1
percent predicted over three years (%)
P1 (8) 62.5 32.6 (10–46) 63.4 (31–84) 12.5 75 16.4 (1–32) 4.4 (0.5 to 11.3)
P6 (6) 33.3 27.4 (20–36) 51.7 (27–112) 16.7 67 11.3 (2–20) 2.7 (−9.5 to 12)
P14 (12) 50 26.7 (13–34) 63 (26–100) 14.3 83 10.3 (0–18) 6.1 (−1.5 to 15)
CP2 (8) 50 25.9 (10–41) 73 (50–115) 0 50 11.6 (0–25) 9.2 (−2 to 21.1)
Others (304) 47 26.5 (1–50) 61.3 (17–113) 24.3 67 11.6 (0–47) 5.8 (−37.5 to 39)
Fig. 3 Phenotypic characterisation of P. aeruginosa isolates belonging to
the four more frequent PFGE profiles. Characterisation of phenotypic
traits of adaptation to CF airways were assayed on 34 P. aeruginosa
isolates belonging to the four major clusters (P1, P6, P14, CP2) identified
by PFGE analysis. The proportion of isolates with a specific phenotypic
trait was calculated and represented for each profile
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Additional file 1: Additional Methods and References; Tables S1.
Demographics of CF patients enrolled in the study; Table S2. Evaluation
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Abbreviations
CF, cystic fibrosis; CP, PFGE correlated profiles; FEV1, forced expiratory volume
in 1 second; MDR, multidrug-resistant; MIC, minimum inhibitory concentrations;
MSLT, multilocus sequence typing; P, PFGE patterns; PFGE, pulsed-field gel
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